Health Trials

Classic Congenital Adrenal Hyperplasia

3

Review clinical trials related to Classic Congenital Adrenal Hyperplasia. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of atumelnant (CRN04894).

Participants needed: 200
Trial details
Phase: Phase 2Age: 16-74Biological sex: AllType: InterventionalSponsor: Crinetics Pharmaceuticals Inc.Updated: Jun 29, 2026Locations: 13
Eligibility criteria

Participants with CAH who have completed the Treatment Period in a Crinetics par... [+8]

Any medical condition(s) or laboratory findings that, in the opinion of the Inve... [+14]

Read more
Status: Recruiting

A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)

The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of atumelnant treatment in pediatric participants with classic congenital adrenal hyperplasia (CAH).

Participants needed: 153
Trial details
Phase: Phase 2, Phase 3Age: 1-17Biological sex: AllType: InterventionalSponsor: Crinetics Pharmaceuticals Inc.Updated: Jun 16, 2026Locations: 35
Eligibility criteria

Male or female at birth, between 1 to <18 years of chronological age at the time... [+5]

Diagnosis of any form of CAH other than classic 21-OHD. [+9]

Read more
Status: Recruiting

A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia

The purpose of this study is to evaluate the efficacy, safety, PK, and PD of atumelnant in adults with classic CAH due to 21-OHD.

Participants needed: 150
Trial details
Phase: Phase 3Age: 18-74Biological sex: AllType: InterventionalSponsor: Crinetics Pharmaceuticals Inc.Updated: Jun 4, 2026Locations: 45
Eligibility criteria

Male or female, between ≥18 to <75 years of age at the time of signing the ICF. [+8]

Diagnosis of any form of CAH other than classic 21-OHD. [+9]

Read more